# Study of the protective OAS1 rs10774671-G allele against severe 1 COVID-19 in Moroccans suggests a North African origin for 2 **Neanderthals** 3 4 Fatima Zohra El Youssfi<sup>1</sup>, Abbas Ermilo Haroun<sup>2,3</sup>, Chaimae Nebhani<sup>1</sup>, Jihane 5

Belayachi<sup>2,4</sup>, Omar Askander<sup>5</sup>, Elmostafa El Fahime<sup>6</sup>, Hakima Fares<sup>7</sup>, Khalid Ennibi<sup>8</sup>, 6

7 Redouane Abouqal<sup>2,3</sup>, Rachid Razine<sup>2,3</sup>, Ahmed Bouhouche<sup>1,9\*</sup>

- 8 9
- 10 1 Laboratory of Human Genetics, Medical School and Pharmacy, University Mohammed V in Rabat,

11 Morocco

- 12 2 Laboratory of Biostatistics, Clinical and Epidemiological Research, Department of Public Health,
- 13 Medical School and Pharmacy, University Mohammed V in Rabat, Morocco
- 14 3 Laboratory of Community Health, Department of Public Health, Medical School and Pharmacy,
- 15 University Mohammed V in Rabat, Morocco
- 16 4 Acute Medical Unit, Ibn Sina University Hospital, Rabat, Morocco
- 17 5 Faculty of Medical Science, Mohammed VI Polytechnic University, Benguerir, Morocco.
- 18 6 Molecular Biology and Functional Genomics Platform, National Center for Scientific and Technical
- 19 Research, Rabat, Morocco.
- 20 7 Intensive Care Department, Cheikh Zaid International Universitary Hospital, Rabat, Morocco
- 21 8 Virology, Infectious and Tropical Diseases Center, Hôpital Militaire d'Instruction Mohammed V.
- 22 Rabat.
- 23 9 Genomic Center of the Cheikh Zaid Foundation, Abulcasis International University of Health
- 24 Sciences, Rabat, Morocco
- 25
- 26
- 27
- 28 \* Correspondence author
- 29 E-mail: a.bouhouche@um5r.ac.ma (AB)
- **ORE** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. In the state of the stateo 30

#### Abstract 31

**Background**: The clinical presentation of COVID-19 has shown high variability 32 between individuals, which is partly due to genetic factors. The OAS1/2/3 cluster 33 was found to be strongly associated with COVID-19 severity. We aimed to 34 examine this locus for the occurrence of the critical variant, rs10774671, and its 35 respective haplotype blocks within the Moroccan population. 36

37 Methods: The frequency of SNPs at the cluster of OAS immunity genes was assessed from an in-house database in 157 unrelated individuals of Moroccan 38 origin. The OAS1 exon 6 was sequenced by Sanger's method in 71 39 asymptomatic/mild and 74 moderate/severe individuals positive for SARS-CoV-40 2. Genotypic, allelic, and haplotype frequencies of three SNPs were compared 41 42 between the two groups. Finally, males in our COVID-19 series were genotyped for the Berber-specific marker E-M81. 43

**Results**: The prevalence of the OAS1 rs10774671-G allele in present-day 44 Moroccans was 40.4%, close to that of Europeans. However, it was found equally 45 on both the Neanderthal GGG haplotype and the African GAC haplotype with a 46 frequency of 20% each. These two haplotypes, and hence the rs10774671-G 47 allele, were significantly associated with the protection against severe COVID-19 48 (p = 0.034, p = 0.041, and p = 0.008 respectively). Surprisingly, among Berber 49 men, the African haplotype was absent while the prevalence of the Neanderthal 50 haplotype was close to that of Europeans. 51

52

Conclusion: The protective rs10774671-G allele of OAS1 was found only in the

53	Neanderthal haplotype in Berbers, the indigenous people of North Africa,
54	suggesting that this region may have served as the stepping-stone for the passage
55	of the hominids to the other continents.
56	
57	
58	Keywords: SARS-CoV-2, COVID-19 severity, 2',5'-oligoadenylate synthetase,
59	single nucleotide polymorphism, Neanderthals, North Africa
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	

# 75 **1. Introduction**

COVID-19, caused by the coronavirus SARS-CoV-2, appeared in November 76 2019 in Wuhan, Hubei province (China), before spreading around the world and 77 78 causing a pandemic [1, 2]. The consequences of SARS-CoV-2 infection vary greatly from person to person and from population to population. While most 79 infected individuals are asymptomatic or minimally symptomatic, some develop 80 severe or even critical illness. Older people and those with underlying medical 81 condition, such as cardiovascular disease, diabetes, chronic respiratory disease, or 82 cancer, are at greater risk of developing a severe form [3]. However, these risk 83 factors alone do not explain the variability in severity observed. These differences 84 could partly result from individual genetic susceptibility. The scientific 85 community has been mobilized to respond to the health crisis to identify the 86 genetic determinants of COVID-19 that protect people from or predispose them 87 to severe manifestations of the disease. A genetic study conducted on patients of 88 European ancestry identified a risk locus for severe COVID-19 in the 2'-5'-89 90 oligoadenylate synthetase 1/2/3 (OAS1/2/3) gene cluster [4]. Subsequently, it was 91 reported that elevated levels of OAS1 in the plasma were associated with reduced COVID-19 susceptibility and severity [5]. 92

This genetic region of chromosome 12q24.13 carries a haplotype of approximately 75 kb of Neanderthal origin [6], where the discovery of the causal variant was possible through studies conducted on a multiancestry cohort including patients from both African and European ancestry. It consists of

97 rs10774671 with G>A transition occurring at a splice acceptor site, where the protective ancestral G allele produces a longer OAS1 transcript and a more active 98 protein [7, 8]. Moreover, OASI SNPs have been reported to be associated with 99 susceptibility to West Nile virus infections [9] and to be involved in altered 100 cellular function leading to several autoimmune and infectious diseases, 101 suggesting that the OAS genes play a critical role in the innate immune response 102 to viruses [10-14]. For instance, the OAS1 enzyme catalyzes the synthesis of short 103 104 polyadenylates, which activate ribonuclease L contributing to the degradation of viral RNA and inhibition of viral replication [15, 16]. It produces five transcripts 105 including p42, p44, p46, p48, and p52, and its expression is stimulated by the 106 interferon system [17, 18]. 107

In this study, we assessed the prevalence of several variants at the OAS gene 108 cluster that comprise the Neanderthal haplotype by analyzing exome data of 157 109 110 unrelated Moroccan individuals and observed that the OAS1 rs10774671-G allele was found on both Neanderthal and African haplotypes. We then investigated the 111 rs10774671 variant in 146 Moroccan volunteers positive for SARS-CoV-2 112 infection and showed that it was significantly associated with COVID-19 severity. 113 114 Interestingly, in Berbers of both paternal and maternal lineages, the African haplotype containing the G allele was absent while the frequency of Neanderthal-115 derived haplotypes is close to that of Europeans. 116

117

118

# 119 Material and methods

#### 120 Frequency of *OAS* gene variants in the Moroccan population

To assess the frequency in the Moroccan population of the Neanderthal haplotype 121 122 at the cluster of OAS immunity genes in the chromosomal region 12q24.13, we analyzed exome data from 157 unrelated patients suspected of having a rare 123 hereditary disease. These patients were recruited from the Department of 124 Neurology of Specialties Hospital and Cheikh Zaid Hospital of Rabat. Part of the 125 data was taken from the in-house exome database and the other part comes from 126 whole exome sequencing (WES) carried out as part of a collaborative project with 127 3Billion® (Seoul, Korea). Data were collected for variants rs1131454, 128 129 rs10774671, rs1131476, rs1051042 and rs2660 in OAS1, rs1859330, rs1859329 and rs2285932 in OAS3, and the variant rs1293767 in OAS2, variants that 130 comprise the Neanderthal haplotype at the OAS locus as described elsewhere [19]. 131 132

133 COVID-19 Patients recruitment

To highlight whether the variants studied are associated with the severity of COVID-19 in the Moroccan population, it was essential to minimize the effects of underlying medical conditions such as comorbidities by reducing the upper age limit of patients. Thus, we have adopted the selection criteria including males or females of Moroccan origin, aged between 18 and 65 years old, with positive RT-PCR test for SARS-COV-2, who have not received any vaccines. Pregnant patients were excluded from the study. 146 COVID-19 patients were enrolled for

1 year between 28 July 2020 to 15 July 2021, a period of the pandemic dominated 141 by the alpha and beta variants. All patients filled out a form concerning socio-142 demographic data for the establishment of ethnicity and medical history, notifying 143 comorbidities, if applicable. Patients were recruited by three different hospital 144 centers involved in a national COVID-19 research consortium, including the 145 Medical Emergency Department (CHU Ibn Sina, Rabat), the Virology 146 Department (Military Hospital, Rabat), and the Intensive Care Unit (Cheikh Zaid 147 148 international university hospital, Rabat). Outcomes were defined as asymptomatic (without symptoms), mild (non-hospitalized), moderate (hospitalized but not 149 requiring invasive ventilation), and severe (hospitalized requiring invasive 150 ventilation or death). 146 patients were recruited and grouped into the following 151 severity categories, asymptomatic (N = 21), mild COVID-19 (N = 50), moderate 152 COVID-19 (N = 48), and severe COVID-19 (N = 27). Asymptomatic and mild 153 154 patients were grouped (N=71) and compared to moderate/severe patients (N=75). Five ml of venous blood was collected in an EDTA tube from each participant 155 and stored at -20°C until DNA extraction. The written informed consent was 156 signed by all patients before their enrollment. This study was approved by the 157 158 ethics committee of Cheikh Zaid Hospital of Rabat (ID: CEFCZ/AB/PR RFG). 159

160 Genetic analysis

161 Genomic DNA (gDNA) of 146 SARS-CoV-2 positive volunteers was extracted
162 using the MagPurix® Blood DNA Extraction Kit with a Zinexts MagPurix EVO

163 24 CE IVD system (Zinexts Life Science Corp., New Taipei City, Taiwan). Quality and concentrations of DNA samples were analyzed by Nanodrop One<sup>c</sup> 164 Spectrophotometer (Thermo Fisher Scientific). PCR amplification, covering the 165 OAS1 exon 6 and its intron boundaries, was performed using two pairs of specific 166 primers (forward: 5'-GTGGCCAGGCTTCTATACCC-3'; and reverse: 5'-167 TGGAGTGTGCTGGGTCTATG-3') designed with Primer3 Input (V 0.4.0). 168 PCR amplification was performed using 100 ng of template gDNA, 1 µL of each 169 primer (10 µM), 5 µL of 5X MyTaq reaction buffer, and 0.2 µl of MyTaq DNA 170 polymerase (Bioline) in a total reaction volume of 25 µL. Thermal conditions 171 were as follows: 95°C for 3 min, 35 cycles of 95°C for 5 sec, 60°C for 15 sec, and 172 72°C for 10 sec, with a final extension of 72°C for 10 min. The PCR products 173 were visualized by 1.5% agarose gel electrophoresis. Five microliters of PCR 174 amplicons were purified using ExoSap IT-express reagent and 2 microliters of the 175 176 product were used for cycle sequencing with BigDye<sup>TM</sup> Terminator v3.1 Ready Reaction Cycle Sequencing Kit. Electrophoresis was performed on SegStudio 177 Genetic Analyzer, and Sequence data were analyzed by SeqScape 4 software 178 (Thermo Fisher Scientific). 179

The genetic marker, E-M81, reported as being the specific male lineage of autochthonous Berbers of North Africa, was analyzed in all 80 males in the COVID-19 positive cohort of patients. The marker was amplified by PCR and Sanger sequenced as described previously [20].

184

#### 185 Statistical analysis

Statistical analysis was performed using *jamovi* software (Version 1.6). The 186 evaluation of demographic variables and disease characteristics was done using 187 descriptive statistics. A chi-square ( $\chi^2$ ) test was used before the association tests 188 to assess deviation from Hardy-Weinberg equilibrium (HWE) in the control 189 group. The genotypic and allelic frequencies were compared between patients and 190 controls to check the associations of the studied SNPs with COVID-19 severity. 191 192 The  $\chi^2$  test was used to identify the differences in genotypic distribution between study groups under an additive genetic model. For allelic and haplotype models, 193 Odds ratios (ORs) at 95% confidence intervals (CI) were estimated using logistic 194 regression analysis, and *p*-values less than 0.05 was considered statistically 195 significant. 196

197

# 198 **Results**

### 199 Frequency of Neanderthal alleles at *OAS* gene cluster in Moroccans

The genotype of 9 SNPs at the cluster of *OAS* immunity genes in the chromosomal region 12q24.13 (Fig 1) was extracted from an exome sequencing database of 157 unrelated individuals, all of Moroccan origin. The results presented in Table 1 showed that, overall, the frequencies of these SNPs in Moroccans are close to the frequency of the minor allele frequency (MAF) of the 1000 genome project. Focusing on *OAS1* variants, the reference G allele of the *OAS1* splice variant rs10774671 represented 40.4% in analyzed Moroccan individuals, close to that of

Europeans with 35.2%, but much lower than that of Africans with 64.0% and much higher than that of Asians with only 27.2%. The frequencies of the missense variants rs1131476 and rs1051042, and the 3'UTR rs2660 variant were 21.1% identical, indicating that they are in complete linkage disequilibrium, which was also the case in the other populations of European, Asian and African ancestry (Table 1).

Fig 1: OAS gene cluster at chromosome 12q24.13 and structural organization of OAS1 giving
the location of the splice variant rs10774671

215

216 We then explored the haplotypes formed by the three SNPs rs10774671, 217 rs1131476, and rs1051042, which allowed for identification of the predominantly protective Neanderthal-derived haplotype in this genetic region. The haplotypes 218 219 consisting of these three SNPs were GGG, GAC, and AAC, and the graphical representation of their distribution in the present-day Moroccans in comparison 220 with different ancestries are shown in Fig 2. The OASI rs10774671-G allele in 221 Moroccans was included in both Neanderthal GGG and African GAC haplotypes 222 with frequencies of 21% and 19.4% respectively. In comparison to other 223 ancestries, the GGG haplotype accounts for 34.5% of Europeans, 27.1% of 224 Asians, and only 2.7% of Africans. The GAC haplotype is however predominant 225 226 in Africans with a frequency of 61.3% and is almost absent in Europeans and Asians with 0.7% and 0.001% respectively. Finally, the risk haplotype AAC was 227 the prevalent haplotype in the Asian population with 72.4% (Table 1). 228

			0451				0463		0452
	rs1131454 c.484G>A	rs10774671 c.1039-1G>A	rs1131476 c.1054G>A	rs1051042 c.1082G>C	rs2660 c.*84G>A	rs1859330 c.53G>A	rs1859329 c.117C>T	rs2285932 c.1314T>C	rs1293767 c.448+41C>G
	p.Gly162Ser	Splice site	p.Ala352Pro	p.Arg361Met	3'UTR	p.Arg18Lys	p.Ala39=	p.lle438=	Intronic
Minor allele frequency	0. 470	0.390	0.210	0.210	0.210	0.340	0.210	0.160	0.150
African Ancestry	0.851	0.640	0.027	0.027	0.027	0.446	0.011	0.010	0.011
Asian Ancestry	0.414	0.272	0.271	0.271	0.271	0.268	0.268	0.156	0.130
European Ancestry	0.425	0.352	0.345	0.345	0.345	0.370	0.365	0.328	0.325
Moroccan population	0.554	0.404	0.210	0.210	0.210	0.283	0.213	0.197	0.194

Table 1: SNP Frequencies of the OAS locus in 157 individuals of Moroccan origin in comparison with those of the 1000 genomes project

Fig 2. Prevalence of the three possible haplotypes with the three OAS1 SNPs studied in 157 individuals of Moroccan origin in comparison with the data of 1000 Genome Project of Africans, Asians and Europeans.

232

#### 233 Association study in Moroccan COVID-19 patients

The demographic and clinical data of the two studied groups are shown in Table 234 2. The mean age and standard deviation of patients asymptomatic/mild were 44.1 235  $\pm$  13.5 years and significantly lower than that of moderate/severe with 51.4  $\pm$  10.5 236 years (p < 0.001). There was no significant difference regarding the sex ratio 237 between the two groups (OR = 1.04, p < 0.897), with a female-to-male ratio of 238 approximately 1:1. As expected, the patients in the asymptomatic/mild group 239 displayed a significantly lower frequency of comorbidity compared to the 240 moderate/severe group (OR = 2.85, p < 0.004), with 22.5% and 56%, respectively. 241 Likewise, the mortality rate was 0% among the asymptomatic/mild patients and 242 8% among moderate/severe patients, which was significantly different (OR = 243 0.07, *p* < 0.015). 244

The distribution of genotypes, alleles, and haplotypes of the three *OAS1* SNPs according to severity were presented in Table 3. Among the 292 alleles analyzed, the ancestral G allele represented 40% for the rs10774671variant and 21.23% for both the rs1131476 and rs1051042 variants. The comparison between the two groups studied, asymptomatic/mild versus moderate/severe, shows a significant difference under both the additive (p = 0.014) and allelic models (OR 0.528 [95% CI 0.329-0.848], p = 0.008). However, no statistically significant differences in

		Diseas	OR (CI 95%)	<i>p</i> value		
	Asymptomatic/Mild (n = 71)				Moderate/Severe (n = 75)	
	No	%	No	%		
Age (y) Mean ± SD	44.1 + 13.5		51.4 + 10.5			<.001
Sex						
Male	39	54.9	41	54.7	1.04 (0.544-2.01)	0.897
Female	32	45.1	34	45.3		
Comorbidity	16	22.5	42	56.0	2.85 (1.39-5.85)	0.004
Mortality	00	0.0	06	8.0	0.07 (0.004-1.35)	0.015

Table 2: Demographic criteria of COVID-19 studied groups

SNP Genetic Model			Asymptomatic/Mild (N= 71)		Moderate /Severe (N = 75)		р	OR (95% CI)	
			Ν	%	N	%			
rs10774671		GG	18	25.3	06	08.0			
	Additive model	GA	32	45.1	37	49.3	0.014		
		AA	21	29.6	32	42.7			
	Allelic model	G	68	47.9	49	32.7	0.008	0.528 (0.329 – 0.848)	
		А	74	52.1	101	67.3	Ref		
rs11314476		GG	05	07.0	02	02.7			
	Additive model	GA	26	36.6	22	29.3	0.248		
		AA	40	56.4	51	68.0			
	Allelic model	G	36	25.4	26	173	0.006	0.617 (0.350 1.090)	
	Anene model	A	106	23.4 74.6	20 124	82.7	Ref	0.017 (0.550 - 1.090)	

Table 3. Comparison of genotypic and allelic distribution of the OAS1 rs10774671 and rs11314476 SNPs between COVID-19 asymptomatic/mild and Moderate/Severe groups.

252 the distribution of the rs1131476 polymorphism were observed between the two study groups under both the additive (p = 0.248), and allelic models (OR 0.617 253 [95% CI 0.350-1.090], p = 0.096), suggesting that this missense mutation was not 254 associated with COVID-19 severity in Moroccans. 255 The comparison of the occurrence of these polymorphisms in their respective 256 haplotype block between the two groups studied is shown in Table 4. The three 257 selected SNPs formed only three haplotypes GGG, GAC and AAC. The two 258 259 haplotypes GGG, and GAC were common in Asymptomatic/Mild versus Moderate/Severe patients and associated compared to the risk AAC haplotype 260 with OR 0.529 [95% CI 0.285 - 0.973], p = 0.034 and OR 0.527 [95% CI 0.028 261 -0.509], p = 0.041 respectively. These two haplotypes thus confer protection 262 against severe COVID compared to the risk haplotype AAC in patients of 263 264 Moroccan origin.

265

Tables 4. The comparison of the haplotype distribution consisting of rs10774671, rs1131462 and rs1051042 between the asymptomatic/mild group versus moderate/severe group

	Asymptomatic/Mild (N= 71)		Moderate (N =	/Severe 75)	р	OR (95% CI)	
	N	%	N	%			
Haplotype							
GGG	36	25.4	26	17.3	0.034	<b>0.529</b> (0.285 – 0.973)	
GAC	32	22.5	23	15.3	0.041	<b>0.527</b> (0.028 – 0.509)	
AAC	74	52.1	101	67.4	Ref		

268

269

270

#### 271 Distribution of OAS1 haplotypes in Berbers

Among the 80 males in our cohort of SARS-CoV-2-positive individuals, 41 were 272 positive and 39 were negative for the E-M81 marker. The distribution of the three 273 haplotypes studied GGG, GAC and AAC in these two groups, as well as that of 274 29 males with Parkinson's disease carrying the LRRK2 G2019S mutation whose 275 Berber origin has been established for both paternal and maternal lineages [20] 276 were presented in Fig 3. The results showed that the prevalence of the African 277 278 GAC haplotype in males with the E-M81 marker represented only 8.5% and was lower than that of males negative for this marker with 25.7%. Furthermore, this 279 GAC haplotype was completely absent in males whose Berber origin concerned 280 both the maternal and paternal lineages. The prevalence of both GGG and AAC 281 haplotypes in these pure Berber males is close to that of European ancestry. 282

283

Fig 3. Frequencies of the three haplotypes consisting of the three OAS1 SNPs studied in 39 males negative and 41 males positive for E-M81 marker, all positive for SARS-CoV-2, and 29 males *LRRK2* G2019S carriers whose Berber origin has been established for both paternal and maternal lineages.

288

# 289 **Discussion**

The clinical presentation of COVID-19 following SARS-CoV-2 infection has shown high interindividual variability, ranging from asymptomatic to death, which is partly due to genetic factors. The chr12q24.13 region containing the *OAS* gene cluster was recently reported to be strongly associated with COVID-19 294 severity and mortality [4], and the rs10774671 splice variant was confirmed to be the functionally critical variant of this chromosomal region that influences the 295 outcomes of SARS-CoV-2 infection [7, 8]. Indeed, the OASI rs10774671-G allele 296 has been shown to increase levels of the p46 isoform and thus the circulating 297 levels of OAS1 protein that were strongly associated with reduced risks of severe 298 COVID-19 [5]. This protective G allele represents about 35% of individuals of 299 European ancestry and was found on a haplotype inherited from the Neanderthal, 300 and it represents 64% of the African population independently of this 301 Neanderthal-derived haplotype [6]. 302

To our knowledge, no data currently exist on the prevalence of OAS gene cluster 303 variants in the North African population, which by its geographical position in the 304 305 African continent could give relevant information on how this G allele at 306 rs10774671 was inherited from the ancestral population common to both modern humans and Neanderthals. Our study thus presents a first insight into this 307 chromosomal region in the Moroccan population, which is culturally, historically, 308 and anthropologically similar to the other neighboring countries of the North 309 African subcontinent. We showed that the frequencies of OAS cluster SNPs in 310 311 Moroccans were close to the MAF of the 1000 genome project, where the OAS1 rs10774671-G allele represented 40.4%. However, analyzing the haplotypes 312 consisting of three OAS1 variants that captured the Neanderthal haplotype showed 313 that the rs10774671-G allele was found equally on both the Neanderthal GGG 314 haplotype and the African GAC haplotype. This distribution seems different from 315

the European population where the G allele was mostly found at 35% in the Neanderthal haplotype, and from the African population where it was mostly found at 64% in a specific African haplotype, as reported before [6-8].

The study of these 3 selected SNPs in a series of 146 SARS-CoV-2 positive 319 individuals of Moroccan origin less than 65 years of age showed that only the 320 splice variant rs10774671 presents a significant association with the severity of 321 COVID-19. Both the AA genotype and the A allele were predictive of severe 322 323 COVID-19 disease, supporting literature findings that this is the only variant of this locus influencing COVID-19 outcomes [7, 8]. However, even though the 324 prevalence of the protective allele OAS1 rs10774671-G in the Moroccan 325 population was close to that of Europeans, the severity and mortality caused by 326 SARS-CoV-2 infection are much higher in individuals of European ancestry, even 327 328 leading to a reduction in life expectancy [21]. This suggests that other genetic factors as well as general health factors and conditions, all interacting in complex 329 330 ways, could be differentially involved between the two populations and remain to be discovered. 331

Furthermore, both the Neanderthal GGG and African GAC haplotypes, containing the rs10774671-G allele were shown to be protective against severe COVID-19. Overall, in the 146 individuals positive for SARS-CoV-2, the frequency of the G allele and of the two GGG and GAC haplotypes were consistent with those obtained in the control cohort of our WES database, thus confirming the equal prevalence of around 20% for each of the two Neanderthal

and African haplotypes in the present-day Moroccans. The presence of the
African haplotype could certainly be due to a recent admixture with sub-Saharan
African populations, while the chronology of the presence of the Neanderthal
haplotype in this population would be difficult to determine precisely.

The Moroccan population is known to be a heterogeneous population having 342 received influences from the south, north, and east, and whose ancient origin was 343 essentially indigenous Berber. To provide elements of answers to the hypothesis 344 345 of the origin of the Neanderthal Haplotype in North Africa, the distribution of the three haplotypes was compared in our series of SARS-CoV-2 positive individuals 346 between males with and without the marker E-M81, known to be the specific male 347 lineage of autochthonous Berbers of North Africa. The frequencies of the African 348 GAC haplotype decreased to 8.5% in favor of the Neanderthal GGG haplotype 349 350 which increased to 29.3% in males with the E-M81 marker compared to males without this marker at a frequency of 23% and 25.7% respectively. GAC 351 haplotypes in males with the E-M81 marker are likely derived from maternal 352 lineage. Surprisingly, the African GAC haplotype was completely absent in 353 Berber males from both paternal and maternal lineages, and whose frequencies of 354 355 the two remaining haplotypes GGG and AAC were similar to those of European 356 ancestry.

These results provide evidence for the presence of the Neanderthal protective haplotype among Berbers who are the ancient indigenous inhabitants of North Africa over the last 10,000 years. However, the question that remains to be asked

is whether this haplotype was imported to North Africa from the "back to Africa" 360 migration or exported to Europe and Asia by the earlier "out of Africa" one. 361 Several recent pieces of scientific evidence lean towards the second scenario. 362 First, it has been reported that present-day North Africans share a majority of their 363 ancestry with Europeans and West Asians but not with sub-Saharan Africans [22-364 24]. Along the same lines and in a slightly earlier period, the genetic study of 365 human fossils from the Taforalt region dating back 15,000 years excluded gene 366 367 flow from Southern Europe into northern Africa, as well as a genetic affinity with early Holocene Near Easterners, suggesting a late Pleistocene connection between 368 North Africa and the Near East [25]. However, due to the absence in this region 369 from ancient genomic data at a similar time, the authors could not define the 370 epicenter or the direction of this connection. 371

The study of the G2019S mutation of the *LRRK2* gene, a founder-effect mutation 372 found in the haplotype 1 identified worldwide but with varying prevalence, was 373 previously determined to originate from a Near-Eastern founder at least 4000 374 years ago and reintroduced by recurrent gene flow to European and North-African 375 populations [26]. Using uniparental markers, we showed that the mutation arose 376 377 in a Berber founder and its epicenter was indeed in North Africa, where the prevalence was the highest with 40%, and the gene flow by migration took place 378 in the opposite direction [20]. 379

In the same way, the site of Jebel Irhoud located in Morocco has provided valuableinformation missing in the puzzle of the history of hominids and in particular their

first exit from Africa to other continents. Irhoud hominids were originally 382 considered as North African *H. sapiens* interbred with Neanderthals, an African 383 form of Neanderthals, or a North African archaic population [27]. Recently, 384 Hublin et al. [28] thermoluminescently dated the Irhoud fossils to 315,000 years 385 ago, making Jebel Irhoud the oldest African hominid site with features of 386 anatomically modern humans and more primitive cranial morphology. 387 Phylogenetic modeling of cranial morphology showed phenotypic affinities of 388 389 Irhoud fossils with both Neanderthals and early *H. sapiens* suggesting that they have been introgressed into Neanderthals at the end of the Middle Pleistocene 390 contributing to the evolution of the Neanderthals [29]. Finally, we performed a 391 whole genome sequencing of only three present-day Moroccans and identified 392 393 over 200,000 SNV absent from 1000G and gnomAD databases, suggesting that 394 the Moroccan population would have more genetic variability and therefore would be older than the European population. Principal components analysis 395 showed that Moroccan genomes form a distinct population and placed them 396 between European and African 1000G populations [30]. 397

Sánchez-Quinto et al. [31] analyzed 780,000 SNPs in individuals from different locations in North Africa including Morocco and showed that North African populations have a significant excess of derived alleles shared with Neanderthals, whereas Sub-Saharan populations are not affected by this admixture event. The authors also showed that the Neanderthal's genetic signal was higher in populations with a local, pre-Neolithic North African ancestry, confirming that

404 this detected ancient admixture is not due to recent Near Eastern or European migrations. Furthermore, the first discovered Neanderthal fossil was at the Jbel 405 Irhoud site [32], where Jean-Jacques Hublin et al. [28] dated the fossils found at 406 300,000 years old, that are accompanied by a Mousterian-type lithic industry, a 407 lithic culture that has long been associated only with Neanderthals in Eurasia. 408 Lithic data (Mousterians) have been reported long before this, and the oldest lithic 409 remains discovered in Morocco belong to the Acheulean and are dated to around 410 411 1.3 million years [33, 34]. These data therefore constitute genomic, fossil and lithic evidence of the existence of Neanderthals in Morocco and their local 412 contributions to anatomically modern humans, reinforcing the idea of a local 413 introgression of the OAS1 rs10774671-G allele. 414

Admittedly. Africa is the cradle of humanity, but the evolution of the hominid 415 ancestors of *Homo Sapiens* did not occur in a linear way within this continent, but 416 rather, through a focus dictated by severe geographical and climatic conditions. 417 Therefore, the evolution of hominids in North Africa, isolated to the south by a 418 largely arid and desert region, would have been different from that of sub-Saharan 419 Africa, and would probably be at the origin of the initial dispersal out of Africa. 420 421 Their conquest of the other continents would have been possible via the Strait of Gibraltar during the Ice Age, and later along the Mediterranean via the Fertile 422 Crescent. The answers to this scenario are most likely to be found in the whole 423 genome sequencing of a large series of present-day individuals and also in 424 hominid fossils from North Africa. 425

# 426 Conclusion

The rs10774671-G allele of *OAS1* confers protection against severe COVID-19 in the Moroccan population. Surprisingly, this protective allele was found in the Neanderthal haplotype in Berbers, the indigenous people of North Africa suggesting that this subcontinent could be the stepping-stone for the passage of the hominids to other continents.

432

- 433 Supporting information
- 434 S1 Table. Demographic, COVID-19 phenotype, genotype and haplotype of 3
- 435 **OAS1 SNP of 146 individuals positive for SARS-COV-2.** (xlsx)
- 436 S1 Table. Genotype of Y-M81 marker in males positive for SARS-COV-2.
- 437 (xlsx)

438

### 439 Acknowledgments

440 We thank all the participants in this study, and 3billion® (Seoul, Korea) for

441 providing part of the whole exome sequencing free of charge.

442

- 443
- 444
- 445
- 446
- 447

# 448 **Author Contributions**

- 449 Conceptualization: Ahmed Bouhouche.
- 450 Formal analysis: Rachid Razine.
- 451 Data Curation: Omar Askander, Elmostafa El Fahime, Ahmed Bouhouche.
- 452 **Funding acquisition:** Ahmed Bouhouche.
- 453 Investigation: Chaimae Nebhani, Fatima-Zahra El Youssfi, Ahmed Bouhouche, Redouane
- 454 Abouqal, Khalid Ennibi, Hakima Fares, Abbas Ermilo Haroun, Jihane Belayachi.
- 455 **Methodology:** Ahmed Bouhouche.
- 456 **Project administration:** Ahmed Bouhouche.
- 457 Supervision: Ahmed Bouhouche.
- 458 Validation: Ahmed Bouhouche.
- 459 Writing review & editing: Ahmed Bouhouche.
- 460

## 461 Data availability statement

462 All relevant data are within the manuscript and its Supporting Information files.

463

#### 464 **References**

- Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019
   (COVID-19): A literature review. J Infect Pub Health. 2020; 13:667-673.
   <u>https://doi.org/10.1016/j.jiph.2020.03.019</u>
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients
  with pneumonia in China, 2019. New Engl J Med. 2020; 382:727–733.
  https://doi.org/10.1056/nejmoa2001017
- 471 3. Ranjan J, Ravindra A, Mishra B. Gender and genetic factors impacting COVID-19
  472 severity. J Family Med Prim Care. 2021; 10:3956-3963.
  473 <u>https://doi.org/10.4103/jfmpc.jfmpc 769 21</u>

- 474 4. Pairo-Castineira E, Clohisey, S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. Genetic
  475 mechanisms of critical illness in COVID-19. Nature. 2020; 591:92-98.
  476 https://doi.org/10.1038/s41586-020-03065-y
- 477 Zhou S, Hill CS, Sarkar S, Tse LV, Woodburn BMD, Schinazi RF, et al. β-d-N 4-5. 478 hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic 479 Infect mammalian cells. Dis. 2021: 224:415-419. to J 480 https://doi.org/10.1093/infdis/jiab247
- 481 6. Zeberg H, Pääbo S. A genomic region associated with protection against severe COVID482 19 is inherited from Neandertals. Proc Natl AcaD Sci USA. 2021; 118:e2026309118.
  483 https://doi.org/10.1073/pnas.2026309118
- Banday AR, Stanifer ML, Florez-Vargas O, Onabajo OO, Papenberg BW, Zahoor M et al.
  Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVIDhospitalization in patients of European and African ancestries. Nat genet. 2022;
  54:1103-1116. https://doi.org/10.1038/s41588-022-01113-z
- 488 8. Huffman JE, Butler-Laporte G, Khan A, Pairo-Castineira E, Drivas TG, Peloso GM, et al.
  489 Multi-ancestry fine mapping implicates OAS1 splicing in risk of severe COVID-19. Nat
  490 genet. 2022; 54:125-127. <u>https://doi.org/10.1038/s41588-021-00996-8</u>
- 491 9. Lim JK, Lisco A, McDermott DH, Huynh L, Ward JM, Johnson B, et al. Genetic variation
  492 in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS pathogens.
  493 2009. 5:e1000321. https://doi.org/10.1371/journal.ppat.1000321
- 494 10. O'Brien M, Lonergan R, Costelloe L, O'Rourke K, Fletcher JM, Kinsella K, et al. OAS1:
  495 a multiple sclerosis susceptibility gene that influences disease severity. Neurology. 2010;
  496 75:411-418. https://doi.org/10.1212/wnl.0b013e3181ebdd2b
- 497 11. Mandal S, Abebe F, Chaudhary J. 2'-5' oligoadenylate synthetase 1 polymorphism is
  498 associated with prostate cancer. Cancer. 2011; 117:5509-5518.
  499 https://doi.org/10.1002/cncr.26219
- Sams AJ, Dumaine A, Nédélec Y, Yotova V, Alfieri C, Tanner JE, et al. Adaptively
  introgressed Neandertal haplotype at the OAS locus functionally impacts innate immune
  responses in humans. Genome Biol. 2016; 17:246. <u>https://doi.org/10.1186/s13059-016-</u>
  <u>1098-6</u>
- Liu X, Xing H, Gao W, Yu D, Zhao Y, Shi X, et al. A functional variant in the OAS1 gene is associated with Sjögren's syndrome complicated with HBV infection. Sci Rep. 2017;
  7:17571. https://doi.org/10.1038/s41598-017-17931-9

- 14. Wu S, Wang Y, Chen G, Zhang M, Wang M, He JQ. 2'-5'-Oligoadenylate synthetase 1 507 508 polymorphisms are associated with tuberculosis: a case-control study. BMC Pulm Med. 509 2018; 18:180. https://doi.org/10.1186/s12890-018-0746-x
- 510 **15.** Choi UY, Kang JS, Hwang YS, Kim YJ. Oligoadenvlate synthase-like (OASL) proteins: 511 dual functions and associations with diseases. Exp Mol Med. 2015; 47:e144. 512 https://doi.org/10.1038/emm.2014.110
- 16. Wickenhagen A, Sugrue E, Lytras S, Kuchi S, Noerenberg M, Turnbull ML, et al. A 513 514 prenylated dsRNA sensor protects against severe COVID-19. Science. 2021; 515 374:eabj3624. https://doi.org/10.1126/science.abj3624
- 516 17. Kjær KH, Pahus J, Hansen MF, Poulsen JB, Christensen EI, Justesen J, et al. Mitochondrial localization of the OAS1 p46 isoform associated with a common single nucleotide 517 518 polymorphism. BMC cell biol. 2014; 15:33. https://doi.org/10.1186/1471-2121-15-33
- 519 **18.** Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, et al. Interferon-α2b Treatment 520 for COVID-19. Front Immunol. 2020; 11:1061. https://doi.10.3389/fimmu.2020.01061
- 521 **19.** Zeberg H, Pääbo S. The major genetic risk factor for severe COVID-19 is inherited from 522 Neanderthals. Nature. 2020; 587:610–612. https://doi.org/10.1038/s41586-020-2818-3
- 523 20. Ben El Haj R, Salmi A, Regragui W, Moussa A, Bouslam N, Tibar H, et al. Evidence for 524 prehistoric origins of the G2019S mutation in the North African Berber population. PLoS 525 One. 2017; 12:e0181335. https://doi.org/10.1371/journal.pone.0181335
- 21. Schöley J, Aburto JM, Kashnitsky I, Kniffka MS., Zhang L, Jaadla H, et al. Life expectancy 526 527 since COVID-19. Nat Hum Behav. 2022; 6(12):1649-1659. changes 528 https://doi.org/10.1038/s41562-022-01450-3
- 529 22. Botigué LR, Henn BM, Gravel S, Maples BK, Gignoux CR, Corona E, et al. Gene flow 530 from North Africa contributes to differential human genetic diversity in southern Europe.
- 531 Proc Natl AcaD Sci USA. 2013; 110:11791-11796. https://doi.10.1073/pnas.1306223110
- 23. Schuenemann VJ, Peltzer A, Welte B, van Pelt WP, Molak M, Wang CC, et al. Ancient 532 533 Egyptian mummy genomes suggest an increase of Sub-Saharan African ancestry in post-534 Roman periods. Nat Commun. 2017; 8:15694. https://doi.org/10.1038/ncomms15694
- 535 24. Pakstis AJ, Gurkan C, Dogan M, Balkaya HE, Dogan S, Neophytou PI, et al. Genetic 536 relationships of European, Mediterranean, and SW Asian populations using a panel of 55
- 537 AISNPs. Eur J Hum Genet. 2019; 27:1885-1893. https://doi.10.1038/s41431-019-0466-6
- 25. van de Loosdrecht M, Bouzouggar A, Humphrey L, Posth C, Barton N, Aximu-Petri A, et 538
- 539 al. Pleistocene North African genomes link near Eastern and sub-Saharan African human
- 540 populations. Science. 2018; 360, 548–552. https://doi.org/10.1126/science.aar8380

- 26. Lesage S, Patin E, Condroyer C, Leutenegger AL, Lohmann E, Giladi N, et al. Parkinson's
  disease-related LRRK2 G2019S mutation results from independent mutational events in
  humans. Hum Mol Genet. 2010; 19:1998-2004. https://doi.org/10.1093/hmg/ddq081
- 544 27. Bruner E, Pearson O. Neurocranial evolution in modern humans: the case of Jebel Irhoud
  545 1. Anthropol Sci. 2013; 121:31-41. https://doi.org/10.1537/ase.120927
- 546 28. Hublin JJ, Ben-Ncer A, Bailey SE, Freidline SE, Neubauer, Skinner MM, et al. New fossils
  547 from Jebel Irhoud, Morocco and the pan-African origin of Homo sapiens. Nature. 2017;
  546:289–292. https://doi.org/10.1038/nature22336
- 549 29. Mounier A, Mirazón LM. Deciphering African late middle Pleistocene hominin diversity
  550 and the origin of our species. Nat Commun. 2019; 10:3406.
  551 https://doi.org/10.1038/s41467-019-11213-w
- 30. Crooks L, Cooper-Knock J, Heath PR, Bouhouche A, Elfahime M, Azzouz M, et al.
  Identification of single nucleotide variants in the Moroccan population by whole-genome
  sequencing. BMC Genet. 2020; 21:111. https://doi.org/10.1186/s12863-020-00917-4
- 31. Sánchez-Quinto F, Botigué LR, Civit S, Arenas C, Avila-Arcos MC, Bustamante CD, et
  al. North African populations carry the signature of admixture with Neandertals. PLoS
  One. 2012; 7:e47765. https://doi.10.1371/journal.pone.0047765
- 32. Arambourg C. Découverte au Maroc d'un crâne de Néanderthalien. Bulletin de la Société
  Préhistorique Française. 1962; 59-7-8:513-514.
- 33. Mohib A, Raynal JP, Gallotti R, Daujeard C, El Graoui M, Fernandes P, et al. Forty Years
  of Research at Casablanca (Morocco): New Insights in the Early/Middle Pleistocene
  Archaeology and Geology. Hespéris-Tamuda, Eléments d'Archéologie préhistorique
  marocaine. 2019; LIV (3):25-56. hal-03067997
- 34. Gallotti R, Muttoni G, Lefèvre D, Degeai JP, Geraads D, Zerboni A, et al. First high
  resolution chronostratigraphy for the early North African Acheulean at Casablanca
  (Morocco) Sci Rep 2021: 11:15340 https://doi.10.1038/s41598.021.94695.3
- 566 (Morocco). Sci Rep. 2021; 11:15340. <u>https://doi.10.1038/s41598-021-94695-3</u>



# Figure 1



